Innovotech Inc. (TSX Venture Exchange: IOT; OTCQB: IOTCF) reported financial results for the first quarter of 2026, revealing a 44% decline in revenue to $648,140 compared to the same period in 2025. The decrease was driven almost entirely by changes in a large project for a major customer, which had been expected to continue through the year. The company reported a net loss of $401,295, compared to net income of $63,523 in Q1 2025, reflecting the impact of underutilized capacity and increased operating expenses.
Gross profit for the quarter was $202,231, with a gross margin of 31.2%, down from 53.6% in the prior year. Margins were negatively affected as the company maintained staffing and operational readiness in anticipation of executing the planned customer work. Operating expenses increased year over year, driven by the integration of Keystone Labs and Innovotech Labs, the relocation of former Keystone Labs operations to a new facility, and investments in a stronger sales organization.
Despite the financial challenges, Innovotech continued its strategic transformation, including strengthening its leadership and commercial teams and completing its OTCQB listing in the U.S. The company maintains a strong liquidity position and a meaningful equity base, which management believes provides flexibility to manage near-term volatility while executing its longer-term strategy. “Management remains committed to investing in a more diversified, resilient, and scalable platform,” said Innovotech CEO Craig Milne. “The Company is continuing to execute its transformation strategy with a focus on the operational and commercial initiatives required to support long-term growth and reduce revenue concentration risk.”
The company, which specializes in contract research, analytical, and microbial testing within regulated healthcare markets, is a recognized leader in biofilm science and antimicrobial testing. Its proprietary MBEC Assay® platform is widely used for high-throughput antimicrobial and antibiotic testing. Innovotech operates through ISO-certified and GMP-accredited laboratories and supports clients across multiple sectors and geographies. The company’s unaudited consolidated financial statements and Management’s Discussion and Analysis have been filed on SEDAR+ and the OTCIQ. More information is available at https://www.innovotech.ca.
The results underscore the risks associated with client concentration, as the company had previously relied heavily on a single large customer. Innovotech’s strategy aims to mitigate this by expanding service offerings and generating more consistent recurring revenue. The company’s forward-looking statements highlight uncertainties including regulatory outcomes, reliance on a small number of customers, and fluctuations in operating results. Investors are cautioned that actual results may differ materially from those expressed or implied by such statements.
